Hosted on MSN2d
MSD halts Winrevair trial due to success of previous study
MSD said that its sotatercept steering committee called for the trial to end as patients are moved to the ongoing open-label ...
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final ...
pharmaphorum3d
MSD adds rocket fuel to Winrevair's engine in PAH
MSD's pulmonary arterial hypertension (PAH) drug Winrevair has been accelerating at a breakneck pace since its launch earlier this year – and data from a new phase 3 study could give it a turbo ...
pharmaphorum2d
MSD leaps on FDA approval of PAH drug sotatercept
MSD’s sotatercept has become the first FDA ... fusion protein, given the trade name Winrevair, has been cleared to improve exercise capacity, improve lung function, and reduce the risk of ...
Hosted on MSN1mon
UK MHRA approves MSD’s pulmonary arterial hypertension therapy
MSD has received the UK Medicines and Healthcare products Regulatory Agency (MHRA) approval for sotatercept, marketed as Winrevair, to treat pulmonary arterial hypertension (PAH) in the adult ...
Pharmabiz1d
Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis
Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis: Rahway, New Jersey Friday, January 31, 2025, 10:00 Hrs [IST] Merck, known as MSD outsid ...